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Abstract: Cardiovascular diseases are the leading cause of mortality worldwide. It is widely known
that non-resolving inflammation results in atherosclerotic conditions, which are responsible for a host
of downstream pathologies including thrombosis, myocardial infarction (MI), and neurovascular
events. Macrophages, as part of the innate immune response, are among the most important cell types
in every stage of atherosclerosis. In this review we discuss the principles governing macrophage
function in the healthy and infarcted heart. More specifically, how cardiac macrophages participate
in myocardial infarction as well as cardiac repair and remodeling. The intricate balance between
phenotypically heterogeneous populations of macrophages in the heart have profound and highly
orchestrated effects during different phases of myocardial infarction. In the early “inflammatory” stage
of MI, resident cardiac macrophages are replaced by classically activated macrophages derived from
the bone marrow and spleen. And while the macrophage population shifts towards an alternatively
activated phenotype, the inflammatory response subsides giving way to the “reparative/proliferative”
phase. Lastly, we describe the therapeutic potential of cardiac macrophages in the context of
cell-mediated cardio-protection. Promising results demonstrate innovative concepts; one employing a
subset of yolk sac-derived, cardiac macrophages that have complete restorative capacity in the injured
myocardium of neonatal mice, and in another example, post-conditioning of cardiac macrophages
with cardiosphere-derived cells significantly improved patient’s post-MI diagnoses.
Keywords: macrophages; cardioprotection; innate immune response; myocardial infarction; cardiac
repair; remodeling
1. Cardiovascular Disease and Global Burden
Cardiovascular diseases (CVD) are the leading cause of death and disability worldwide [1].
CVD are a class of diseases which affect the heart, blood vessels, and the vasculature of the
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brain [1]. CVD include but are not limited to atherosclerosis, heart disease, ischemic heart
disease, cerebrovascular disease, ischemic stroke, hemorrhagic stroke, hypertensive heart disease,
cardiomyopathy and myocarditis, atrial fibrillation and flutter, aortic aneurysm, peripheral vascular
disease, and endocarditis [2]. According to 2015 mortality data, CVD claimed an estimated 17.9 million
deaths globally, more than cancer and chronic lower respiratory disease combined [3]. Disability
adjusted life-years (DALYs), is a measurement for the number of years lost due to illness, disability,
and early death. In 2016, global CVD burden was estimated to be 353 million DALYs compared to 308
million DALYs in 2000 [4].
2. Overview of Atherosclerosis
Atherosclerosis is an inflammatory disease characterized by the hardening and narrowing of
an artery due to the accumulation of lipids, immune cells, ribonucleic acids and various fibrous
elements [5–8]. Over time these accumulations develop into atherosclerotic plaques that can occlude
blood vessels resulting in reduced blood flow and may lead to acute thrombotic complications [9–14].
Thrombotic events arise when vulnerable plaques rupture, exposing vascular structures to circulation
setting off a coagulation cascade forming a thrombus [12,15]. This thrombus may either form a
stationary blockage completely occluding the blood vessel leading to symptoms of acute ischemia,
or break loose from the initial formation site and become lodged elsewhere potentially resulting in
myocardial infarction (MI), pulmonary embolism (PE), or stroke [12,16–21]. As extensively described
in this review, macrophages play a central role in stoking inflammation in the cardiovascular network.
Recent clinical studies aimed at attenuating inflammation in CVD through inhibition of IL-1β is a
powerful testament to the importance of inflammation in CVD [22,23].
3. Macrophage Roles in Thrombus Formation
Early development and progression of atherosclerosis predominantly occurs within arterial areas
which experience disturbed laminar flow such as arterial branch points and bifurcations [24]. In
these areas, low-density lipoprotein (LDL) and apolipoprotein B-containing lipoproteins accumulate
within the sub endothelial space where they are subject to modification by reactive oxygen species
(ROS) and various enzymes [11,24–27]. Monocytes infiltrate the vascular intima, differentiate into
macrophages, and phagocytize modified LDL within the surrounding tissues. Macrophages are
unable to regulate metabolism of modified lipid species and become lipid-laden foam cells leading
to dysregulation of inflammatory signaling, endoplasmic reticulum (ER) stress, and eventually cell
death [28–33]. Proliferation of smooth muscle cells assist in the formation of a fibrous cap on the luminal
side of the plaque, contributing to plaque stability [34]. As atherosclerosis progresses, disruption
of macrophage-mediated efferocytosis fails to effectively clear cellular debris and oxidized lipids,
leading to the development of a necrotic core within the plaque [24,35,36]. Metabolically dysfunctional
macrophages together with necrosis, release proteolytic enzymes capable of thinning the protective
fibrous cap [24,37,38]. Matrix metalloproteinases (MMPs) produced by macrophages can degrade
various types of extracellular matrix (ECM) proteins [24]. MMP-2 and MMP-9 are hypothesized to
play a role in fibrous cap thinning and plaque rupture [13,24,39]. Rupture of an atherosclerotic plaque
may lead to life threatening conditions such as a myocardial infarction, stroke, pulmonary embolism,
and limb ischemia [12,19,21,40,41]. Recent evidence has demonstrated that macrophage interactions
with platelet-derived chemokines play a crucial role in atherothrombotic risk. CXCL4 is released from
platelet alpha granules which stimulates the release of other store proteins including the chemotactic
cytokines; CCL3 (MIP-1α), CCL5 (RANTES), and CCL7 (MCP-3) [42–44]. Transcriptomics revealed
that CXCL4 induces a novel alternatively activated macrophage termed “M4”, and data has also shown
that M4 macrophages are significantly associated with atherosclerotic plaque stability and vascular
inflammation [45–47].
While the majority of MI events occur as a function of fibrous cap rupture due to inflammatory
and proteolytic degradation by macrophages and constituents of the necrotic core, another phenotype
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of MI is responsible for nearly 30% of all thrombotic events and results from plaque erosion and
thrombus formation without rupture of the fibrous cap [48,49]. And although macrophages have
long been accepted as the purveyor of MI, studies have shown that plaque erosion is associated with
less lipid/plaque burden, a greater abundance of smooth muscle cells, and a comparatively small
macrophage population [50–53]. Consequences of such limited macrophage content associated with
plaque erosion in contrast to macrophage-dependent plaque rupture have yet to be determined, and
the mechanism of erosion vs. rupture requires further exploration.
4. Macrophages: Inflammation and Activation
As the macrophage is the predominant cell type in all stages of atherosclerosis, phenotypic
heterogeneity and functional plasticity are fundamental to a given inflammatory response. Resolving
inflammation is a regulated inflammatory process which relies on immune cells to maintain systemic
homeostasis [54]. This is accomplished by immediate elimination of foreign pathogens, resolution
of sterile inflammation by removal of endogenous pathogens, and maintenance of proper wound
healing and tissue repair [55]. Following the clearance of inflammatory elements, most macrophages
leave the inflammatory site or undergo apoptosis [56]. In contrast, non-resolving inflammation
is chronic in nature as its underlying cause persists for an extended period of time [57]. Cancer,
arthritis, and atherosclerosis are all examples of non-resolving inflammation in which infiltration
and accumulation of monocytes, dendritic cells, and macrophages induce a continuous inflammatory
cascade [58–60]. The physiological environment is responsible for generating different subtypes of
macrophages that display varying degrees of activation. Macrophage activation produces distinct
functional phenotypes that are most commonly categorized using the Th1/Th2 T cell polarization
paradigm, whereby M1 macrophages are representative of pro-inflammatory characteristics and M2
macrophages are associated with tissue repair and wound healing [61,62]. Clearly, this is an overly
simplistic view of macrophage behavior. However, the general guidelines that advise the M1 and M2
nomenclature are useful as a basic delineation of macrophage phenotypes.
M1 macrophages are described as being “classically” activated. M1 activation of macrophages can
be initiated by recognition of pathogen-associated molecular patterns (PAMPs) like lipopolysaccharide,
chitin, and other intracellular pathogens. In addition, damage-associated molecular patterns (DAMPs)
resulting from tissue/cell damage and necrosis are also capable of promoting inflammation. Typically,
PAMPs and DAMPs bind to pattern recognition receptors (PRRs) located on the surface of macrophages.
Toll -like receptors (TLRs) are one of five types of PRRs associated with macrophage activation [63–66].
During an innate immune response, TLR agonists engage the MYD88-dependent pathway including
IRAK4, TRAF6, and IKKβ ultimately leading to activation of NF-κB. The inflammatory function of this
pathway in M1 macrophages is essential to innate immunity in response to pathogenic stimuli. NF-κB
activity in M1 macrophages results in transcription of pro-inflammatory cytokines: IL-1B, IL-6, IL-12,
TNF-α, as well as chemokines involved in immune cell recruitment and invasion. M1 macrophages also
encourage differentiation of inflammatory T-cell phenotypes which further participate in mediating
inflammation [67,68]. IFN-γ is also known to promote M1 activation. It is a potent microbicidal,
cytotoxic effector that is transiently produced by natural-killer cells (NK) and sustained production
is achieved by Th-1 cells. IFN-γ relies on the JAK/STAT signaling pathway which is initiated by
receptor-ligand interaction with IFN-γ receptor 1 and 2 (IFNGR1/2) [69]. It has recently been shown
that IFN-γ and TLR mediated signaling pathways have a synergistic effect on promoting the M1
macrophage phenotype with tumoricidal function. The resultant macrophage population produces
nitric oxide (NO), TNF-α, IL-12p40, and IL-12p70 while the presence of IFN-γ suppressed macrophage
secretion of IL-10 is induced by TLR agonists [70]. During the innate immune response, classically
activated macrophages produce pro-inflammatory cytokines which play a key role in host defense.
However, prolonged exposure to such compounds can result in extensive damage to the host. This is
the case in various inflammatory diseases [71–73].
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Alternatively activated macrophages (M2) are characterized as having proliferative and wound
healing properties. M2 macrophages promote collagen synthesis, fibrosis, and other tissue remodeling
functions [74]. Further, this macrophage phenotype displays elevated expression of scavenger receptors
(SR), mannose receptors (MR), and galactose receptors. Alternatively activated macrophages secrete
cytokines: Transforming growth factor-β (TGF-β) and IL-10, chemokines: CCL17, CCL22, CCL24, and
the enzyme arginase-1 in mice (ARG 1), which participates in cell proliferation, collagen formation, and
tissue repair [74–76]. M2 polarization of macrophages is commonly accomplished by stimulation of the
glucocorticoid receptor (GCR), IL-10 receptor (IL-10R1), and antigens recognized by the Fc family of
receptors [76]. IL-4 and IL-13-mediated alternative activation represents the most extensively studied
variation of M2-macrophage plasticity. Both of these Th 2-related cytokines are expressed by T cells, B
cells, mast cells, and macrophages. Aside from down regulating many of the cytokines associated with
M1 activation, IL-4 and IL-13 induce fibrogenesis through expression of fibronectin-1 (FN-1) and beta 2
integrins. They also modulate tissue repair and cell proliferation signaling via insulin-like growth factor
1 (IGF-1) [77,78]. Aberrant expression of IL-4 and IL-13 has been associated with fibrosis in different
disease states and tissues [79,80]. The term “alternative activation” refers to any activation state other
than “classically” activated. Therefore, it should be noted that alternatively activated macrophages
exhibit a growing spectrum of phenotypic and functional varieties. M2 macrophages can be induced
by different stimuli as previously mentioned, and accordingly have specific classifications denoted by
the stimulus and effector function. M2a macrophages are elicited by Th-2 cytokines, IL-4 and IL-13
while M2b activation is triggered by Fc-γ receptors and TLR stimulation, and M2c macrophages can be
obtained by GC, IL-10, or TGF-β ligands [81].
5. Cardiac Macrophages
Tissue-resident macrophages have been identified in a number of different organs where
they engage in maintaining homeostatic conditions and tissue regeneration. Mouse models have
demonstrated that tissue-resident macrophages found in the liver, brain, lung, skin, and heart
derive from an embryonic lineage, distinct from those of monocytic progenitors [82–87]. These
studies and others also highlight the observation that tissue-resident macrophages maintain a
self-proliferative population throughout adulthood, which is independent of monocyte-derived
macrophage recruitment and declines with age [88–90]. The majority of resident cardiac macrophages
were found to be established prior to birth, and yolk sac progenitors are the primary source of this cell
population [91]. Essentially, the development of advanced gene fate-mapping techniques has shown
that, in the steady-state, two resident cardiac macrophage subsets are present: MHC-IIlowCCR2- and
MHC-IIhighCCR2- cells. Resident cardiac macrophages replenish through tissue proliferation, and
comprise the largest subpopulation of cardiac macrophages [91,92]. Under inflammatory conditions,
a third macrophage subtype can be found in the heart and is classified as MHC-IIhighCCR2+ cells.
Originating completely from bone marrow-derived monocytes, the population of this macrophage
subtype is recruited during inflammation and ultimately replaces embryo-derived cardiac macrophages
as their proliferative properties diminish with age [91,93]. Circulating CCR2+ monocytes interact
with the CCR2 ligand, MCP-1 (CCL2), which is a chemotactic cytokine that potentiates macrophage
recruitment and invasion [94]. Cardiac tissue injury initiates an influx of CCR2+ macrophages which
produce IL-1β, pro-inflammatory cytokine associated with atherosclerosis [22,91]. On the other
hand, resident CCR2- macrophages primarily originating from an embryonic progenitor facilitate
processes of angiogenesis and cardiomyocytes proliferation, roles that are similar in developmental
and neonatal macrophages [95,96]. Bajpai et al. demonstrated that the depletion of resident cardiac
CCR2- macrophages in a murine model of myocardial infarction increased infarct area, reduced left
ventricular (LV) systolic function, and exaggerated LV remodeling [97]. Another study investigated
the therapeutic potential of resident cardiac macrophages by administering a selective CCR2 inhibitor
in a mouse model of cardiac injury. CCR2 inhibition blocked monocyte recruitment and preserved the
populations of MHC-IIlowCCR2- and MHC-IIhighCCR2- resident cardiac macrophage subsets. As a
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result, decreased mRNA and protein expression of MCP-1, IL-1-β, IL-6, and TNF-α was observed in
injured mice that received the CCR2 inhibitor compared to vehicle control [96]. Further exploration
into resident cardiac macrophages as a target for improved outcomes after myocardial infarction is
indeed warranted.
Monocyte-derived macrophages are characterized as MHC-IIhighCCR2+ cells which are
highly recruited to the heart under atherosclerotic conditions and following myocardial insult.
As atherosclerosis develops and progresses, monocytes are recruited to lesions where they accumulate
and contribute to atheromatous plaque formation. Unlike Ly-6CLow monocytes which are far less
invasive, Ly-6CHigh monocytes induce excessive monocytosis, accumulate in lesions, and differentiate
into macrophages [98,99]. Ly-6CHigh Monocytes are inflammatory and rely on CCR2, CCR5, and
CX3CR1 to infiltrate plaque sites [100]. Further, Combadière et al. found that inhibition of CCL2,
CCR5, and CX3CR1 abrogated monocytosis and trafficking of Ly-6CHigh monocytes, which abolished
atherosclerosis by up to 90% in hypercholesterolemic mice [101].
6. Macrophages in Homeostasis
In the healthy heart, mouse models reveal the presence of a significant number of resident cardiac,
yolk sac-derived MHC-IIlowCCR2- and MHC-IIhighCCR2- macrophages expressing low levels of
Ly-6C and exhibiting an M2 polarization profile [102]. It has recently been demonstrated that local
proliferation of these resident tissue macrophages is the major source of cardiac macrophages in
the steady-state [91,103]. Data published by Epelman et al. utilized the proliferation marker Ki-67
to demonstrate the rapid proliferation of resident cardiac macrophages in the heart after MI, while
proliferative activity is completely ablated in monocytes recruited from the circulation once they have
differentiated into macrophages [91]. Conversely, experimental mouse models have revealed that
circulating monocytes contribute to inflammatory mechanisms that precede different forms of cardiac
pathology. SiRNA silencing of CCR2 mRNA in monocytes prevented monocyte accumulation in
inflammatory regions and in atherosclerotic plaques, and reduced infarct size after coronary artery
occlusion [104]. Resident cardiac MHC-IIlowCCR2- and MHC-IIhighCCR2- macrophages express
high levels of myeloid epithelial reproductive tyrosine kinase (MerTK), a critical receptor involved in
macrophage efferocytosis. Deficiency of this protein results in inefficient removal of cell debris during
cardiac repair, increased infarct size, and depressed cardiac function [105].
7. Macrophages in the Aging Heart
As is the case with most diseases and disorders, age is a major risk factor in cardiac-related
morbidity and mortality. Aging in the heart is often characterized by a number of dysfunctional
conditions including: Myocardial sarcopenia, hypertrophy, vascular hyperpermeability, fibrosis,
inflammation, and functional impairment [106–108]. Direct changes in the myocardium and not
ventricular load as a result of hypertension is responsible for such alterations in heart condition
and function [109]. Employing genetic fate-mapping techniques along with parabiotic and chimeric
bone marrow mouse models, Molawi et al. essentially demonstrated that the self-renewal of yolk
sac-derived resident macrophages declines with age. Thus, population dynamics in the aging heart
shifts in favor of monocyte-derived macrophages even in the absence of inflammation [93]. These
examples represent a collective body of data that grows more compelling with the assertion that
resident cardiac macrophages hold much potential in the way of therapeutic intervention for a wide
array of cardiac disorders.
8. Pathology and Resolution of Myocardial Infarction
Myocardial infarction (MI) is one of many pathological etiologies associated with cardiovascular
disease. In the pathologic context MI is defined as cardiomyocyte death due to ischemic insult. Such
events occur as a function of an imbalance in the relation between myocardial oxygen supply and
demand. The continuous development of atherosclerotic plaque in the vasculature results in occlusion
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of the vessel lumen. Luminal narrowing of ≥75% can go undetected while at rest, but as oxygen
demands increase with activity, the obstructed blood flow does not allow for proper oxygenation of
tissues. The most common underlying cause of MI is the incidence of plaque instability in atherosclerotic
disease [110]. Stability in the atheromatous plaque is dependent on the structural integrity of the fibrous
cap. Plaque rupture or erosion introduces thrombi into the circulation where they can cause thrombotic
embolism and acute MI [111]. Occlusion of coronary blood flow prevents aerobic metabolism leading
to rapid ATP depletion and metabolite accumulation. Critical systolic dysfunction is observed within
seconds of ischemic insult and has been shown to cease entirely after 60 s [112,113]. The effects of
ischemic insult are completely reversible so long as the duration is <15–20 min. In large animal models,
prolonged periods of ischemia (60 Minutes) causes continuous cell death of cardiomyocytes in the
ischemic region [114–116]. After a significant MI, cardiomyocytes undergo extensive cell death. The
mammalian heart has only limited regenerative capacity, and therefore the large number of deceased
cells are replaced by non-contractile scar tissue derived from collagen and ECM production. Although
this scar tissue is largely nonfunctional, it is crucial to the maintenance of cardiac structural integrity
and organ function. This reparative process following MI generally takes place in a two-tiered fashion;
an inflammatory stage in which a massive influx of immune cells are recruited to the ischemic region
where macrophages and neutrophils mediate eﬄux of necrotic debris, and a reparative/proliferative
phase that involves the release of growth factors accompanied by extracellular matrix formation,
collagen synthesis, and scarring [117–121]. Dysregulation of the inflammatory response associated
with severe MI can result in adverse remodeling, increased risk of repeat events, and pervasive fibrosis
that ultimately compromises cardiac function [122].
9. Macrophages in Myocardial Infarction
As previously mentioned, cardiac macrophages are of two distinct lineages: Yolk sac-derived
MHC-IIlowCCR2- and MHC-IIhighCCR2- macrophages and MHC-IIhighCCR2+ monocyte-derived
macrophages. Over time, resident developmental macrophages are progressively replaced by
macrophages differentiated from bone marrow-derived and splenic monocytes. Macrophages are
among the most abundant cell types in the infarcted heart. Circulating monocytes from the bone
marrow and spleen are recruited to the infarcted area, and experimental evidence demonstrates the
importance of MCP-1 and its receptor, CCR2, in the process of leukocytosis [123,124]. The monocyte
response to MI proceeds in a biphasic manner whereby distinct monocyte phenotypes are responsible
for the expression of CCR2 by damaged cells. MI initiates recruitment of Ly-6CHigh monocytes
from the bone marrow and spleen to the infarcted region. This inflammatory monocyte subtype
is highly invasive and is among the first cells to arrive at the infarct zone. Ly-6CHigh monocyte
numbers reach their peak approximately three days after injury [125]. From days 1–3 monocytosis
facilitates the influx of monocytes which accumulate and differentiate into macrophages. This is
referred to as the inflammatory phase in which macrophages and neutrophils clear dead cells and
cell debris. The reparative phase is a result of proper resolution of the inflammatory phase, and
is characterized by phenotypic transition of inflammatory monocytes and macrophages (Ly-6CHigh
monocytes and M1 macrophages) to the anti-inflammatory subtypes of the cells (Ly-6CLow monocytes
and M2 macrophages). Over the ensuing days fibroblasts proliferate contributing to scar formation.
Revascularization of tissues is initiated by monocyte/macrophage production of vascular endothelial
growth factor (VEGF) and TGF-β [96,125]. Disfunction of either phase can have profoundly deleterious
effects and understanding the mechanics of these elegantly orchestrated processes is essential to the
development of novel therapeutic interventions.
As early as 30 min after MI, Ly-6CHigh monocytes are recruited from the circulation and infiltrate
the infarct zone via MCP-1/CCR2 interactions [126]. Monocyte numbers reach their peak at around day
three at which point they accumulate and undergo differentiation into macrophages. Determination
between monocytes and macrophages in mouse models is achieved by the differential expression
of F4/80/I-Ab/CD11c as well as CD64 and MerTK. Monocytes are classified as F4/80/I-Ab/CD11cLow
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and express only CD64, while macrophages are F4/80/I-Ab/CD11cHigh and express both MerTK and
CD64 [91,125,127]. Between days 5–7 macrophage populations within the infarct are at their maximum
as illustrated by a mouse model of MI [128,129]. At this stage, classically activated macrophages
dominates the cell population of the infarcted area. M1 macrophages secrete pro-inflammatory
cytokines like TNF-α, IL-1β, IL-6 and MMPs, thereby enhancing the pro-inflammatory response and
facilitating breakdown of collagen and ECM. It is postulated that pro-inflammatory macrophages
play an integral role in preparing the infarcted tissue for repair by removing apoptotic immune cells,
dead monocytes, cell debris, and ECM components [130]. The post-MI inflammatory phase gradually
subsides and macrophages are again a focal cell type in the process of wound healing. Phagocytosis by
macrophages is required for proper initiation of the post-MI wound healing response [131]. Inadequate
suppression or extended duration of the pro-inflammatory response that occurs after MI can have
serious pathological consequences that include: Cardiomyocyte death, impaired systolic function,
chamber dilation due to extensive matrix degradation, compromised ventricular wall integrity, cardiac
rupture, and fibrosis [132].
10. Macrophages and Tissue Repair after MI
The proliferative phase after MI is demarcated by a shift in the polarization profile of macrophages
in the infarcted zone from M1 to M2 phenotype. Depletion of cardiac macrophages with clodronate
showed that both M1 and M2 macrophage phenotypes are present in the infarcted area and contribute
to tissue remodeling, albeit with divergent roles and effects [128]. A second “wave” of monocytosis
takes place once the initial inflammatory phase recedes. The pool of cardiac macrophages is replenished
as Ly-6CLow monocytes are extensively recruited to infarcted tissues where they accumulate and
undergo differentiation into alternatively activated macrophages. M2 macrophages secrete IL-10, which
depresses the pro-inflammatory effects of M1 macrophages, and TGF-β; a cytokine that initiates tissue
remodeling and angiogenesis. Shirishi et al. utilized a mouse model with a deletion of the Trib1 gene.
This model of impaired M2 macrophage activation allowed them to determine cell type-specific effects
of M2 macrophage depletion on post infarct remodeling. When compared to control animals, Trib-/-
mice exhibited severely diminished reparative function following MI, including: Reduced collagen
synthesis and resultant cardiac rupture. The impaired healing process was completely rescued by the
introduction of exogenous M2 macrophages. Furthermore, it was shown that administration of IL-4,
which is a well-known activator of M2 macrophages also rescued the dysfunctional genotype [133].
Macrophage heterogeneity in the post-MI heart has profound implications on its ability to promote
healing and retain functionality.
11. Macrophage-Targeted Pharmaceutical Interventions
Statins are a class of drugs that inhibit the liver enzyme β-hydroxy β-methylglutaryl-coenzyme A
(HMG-CoA) reductase. This effect is designed to reduce the development of atherosclerotic plaque
and protect from repeat infarction [134]. Aside from there lipid lowering qualities, statins have
exhibited anti-thrombotic and anti-inflammatory properties [135]. Kwak et al. found that pravastatin
inhibited IFN-γ-induced macrophage activation [136]. It was also demonstrated by Ghittoni et al. that
simvastatin interrupted MHC class II interactions between macrophages and the adaptive immune
complex [137].
ACE inhibitors (ACEi) have also been highlighted as possible cardioprotective pharmaceutical
therapies. While it’s original usage was prescribed to inhibit circulating angiotensin II (ATII) to
concentration, it also mitigates the pro-inflammatory effects of ATII [138–140]. In murine mouse
models, enalapril reduced ATII-stimulated monocyte recruitment from splenic reservoirs into the
myocardium during MI and subsequently improved ejection fraction by 14%, while at the same time
mitigating vascular inflammation [141]. In a separate study, enalapril administered after MI resulted
in significant reduction in plasma levels of MCP-1 and reduced accumulation and activation of both
monocytes and macrophages in patients with MI [142].
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12. Cell-Mediated Cardioprotection in MI
As mentioned earlier in this review, yolk sac-derived, MHC-IIlowCCR2- and MHC-IIhighCCR2-
macrophages are the predominant immune cell type in the healthy heart. This unique population
of macrophages decreases with aging and after MI, when they are replaced by the bone marrow
derived macrophages (BMDM) via the circulation. This subset of resident, cardiac-tissue macrophages
resembles the M2 phenotype and displays cardioprotective attributes post-MI [133]. Although proper
infarct healing involves the formation of a functional scar, it has been observed in murine neonates
that the distinct population of resident embryonic macrophages is capable of complete restorative
repair [96,143]. Newly published work by Dick et al. revealed the importance of resident cardiac
macrophages in proper remodeling. [144] The authors utilized a Cxcr1-based method of macrophage
depletion coupled with a green fluorescent protein (GFP) label that enabled specific phenotype selection
and cell mapping. Despite accounting for only 2–5% of the cardiac macrophage population during the
initial weeks post MI, depletion of the cells prevented normal infarct healing and adversely affected
cardiac function. And while recruited macrophages were nearly identical to the depleted resident
macrophages, they were unable to adopt the same phenotypic specificity [144]. Clearly, resident cardiac
macrophages are a novel method of cell-mediated cardio protection. Further work is necessary to
better understand what clinical applications these cells may hold.
13. Cardioprotection through Cellular Post-Conditioning
The well-regulated involvement of macrophages in each phase of MI suggests that interactions with
other cell types affect macrophage behavior. In another example of cell therapy for MI, investigators
have found that paracrine signaling from cardiosphere-derived cells (CDC) modulate macrophage
activation promoting a phenotypic switch from M1 to M2 [145,146]. CDCs are essentially cardiac
mesenchymal stem cells. Moreover, they exhibit clonogenicity and the potential for multi-lineage
differentiation [147]. Multiple animal models have been used to examine the efficacy of CDCs in cellular
post-conditioning as a means of ameliorating MI-associated pathology [148]. Intra-coronary infusion
of CDCs resulted in decreased infarct size and reduced microvascular occlusion after 48 h in a porcine
model [149]. Similarly, a mechanistic study performed in rats with acute MI found that intracoronary
infusion of CDCs after 20 min of reperfusion resulted in diminished infarct size and a greater degree of
functional recovery. Further, these authors showed that CDCs promoted the alternative activation of
macrophages toward a cardioprotective phenotype. Macrophages preconditioned with CDCs were
also adoptively transferred after reperfusion and effectively reduced infarct size. Thus, illustrating
the interplay between various cells involved in cardiac preconditioning [146]. While the relationship
between CDCs and macrophages has only recently been studied, the efficacy and safety of CDCs has
been well documented in animal and human subjects [150–153]. Cellular post-conditioning is especially
attractive because of its ability to be administered after an MI event has occurred. Encouraging results
and a growing breadth of insight regarding CDCs and macrophages hold much promise for this
novel treatment.
14. Concluding Remarks
The dynamic mechanisms that govern tissue repair and wound healing are inextricably intertwined
with those that mediate inflammation and immunity. The data reviewed here describes a tightly
regulated sequence of events from infarction to remodeling that is dependent on different populations
of macrophage phenotypes throughout the various stages of myocardial infarction, as summarized
in Figure 1. Both M1 and M2 macrophages are required for healing cardiac tissue and preserving
functional architecture. Cardioprotection is an intriguing therapeutic technique. However, numerous
publications have exposed the elusive nature of this concept. Recent studies are reintroducing
much-needed enthusiasm into understanding the cardioprotective potential of cardiac macrophages.
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As insight beckons effort and innovation, it is imperative that we expand our comprehension of
macrophage contributions to cardiac health.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 9 of 18 
 
 
Figure 1. The Cardiac macrophage population, while the heart is in homeostasis, consists primarily 
of yolk sac-derived macrophages. However, these resident tissue macrophages diminish in number 
with age and are replaced by circulating bone marrow-derived monocytes even in the absence of 
inflammation. BMDM replenish the cardiac macrophage supply, and exhibit M2 activation in the 
steady-state heart. The inflammatory phase of acute myocardial infarction initiates an immune 
response by monocytes/macrophages, which are recruited to the injured tissue. Ly6CHigh monocytes 
infiltrate and accumulate in the injured area where they differentiate into “classical” M1 
macrophages. M1 macrophages secrete pro-inflammatory cytokines and MMPs upon activation by 
DAMPs. The inflammatory response peaks at around day 5–7 and ultimately results in clearance of 
dead cells and cell debris, processes essential for tissue repair. Resolution of inflammation after MI 
marks the beginning of a proliferative phase. During which, circulating Ly6CLow monocytes 
infiltrate the infarcted area. Thus, the population of cardiac macrophages begins to move toward 
alternative activation. The presence of M2 macrophages suppresses inflammation, enhances tissue 
repair and promotes angiogenesis by the expression of TGF-β and IL-10. Dysregulation of either the 
inflammatory or proliferative phase can produce severe outcomes like ventricular weakening, 
fibrosis, and compromised function. Macrophages can participate in cardioprotection via cell-
mediated mechanisms. For example, yolk sac-derived cardiac macrophages are required for 
reparative mechanisms of wound healing. Further, the identical phenotype in murine neonates has 
full regenerative capacity after MI and remains through adulthood although it diminishes greatly 
over time and post-MI. CDCs are another example of cellular cardioprotection. The cardiac type of 
mesenchymal stem cell, CDCs have the potential to induce M2 activation in macrophages. Post-
conditioning of macrophages with CDCs results in an alternatively activated phenotype, which has 
been shown to improve prognosis following myocardial infarction. Abbreviations: BMDM; bone 
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Figure 1. The Cardiac macrophage population, hile the heart is in homeostasis, consists primarily
of yolk sac-derived macrophages. Ho e r, t s r si t tissue acrophages diminish i number
with age and are replaced by circulating bone i ed onocytes even in the absence of
inflam ation. BMDM replenis t r hage su ply, and exhibit M2 activation in the
steady-sta e heart. The infla f te yocardial infarction initiates an i mune
response by monocytes/macrophages, which are re t e injured ti sue. Ly6CHigh m nocytes
infiltra e and accumulate in the injured area where they differentiate into “classical” M1 macrophages.
M1 macrophages secrete pro-inflammatory cytokines and MMPs upon activation by DAMPs. The
inflammatory response peaks at around day 5–7 and ultimately results in clearance of dead cells and cell
debris, processes essential for tissue repair. Resolution of inflammation after MI marks the beginning of
a proliferative phase. During which, circulating Ly6CLow monocytes infiltrate the infarcted area. Thus,
the population of cardiac macrophages begins to move toward alternative activation. The presence
of M2 macrophages suppresses inflammation, enhances tissue repair and promotes angiogenesis
by the expression of TGF-β and IL-10. Dysregulation of either the inflammatory or proliferative
phase can produce severe outcomes like ventricular weakening, fibrosis, and compromised function.
Macrophages can participate in cardioprotection via cell-mediated mechanisms. For example, yolk
sac-derived cardiac macrophages are required for reparative mechanisms of wound healing. Further,
the identical phenotype in murine neonates has full regenerative capacity after MI and remains through
adulthood although it diminishes greatly over time and post-MI. CDCs are another example of cellular
cardioprotection. The cardiac type of mesenchymal stem cell, CDCs have the potential to induce M2
activation in macrophages. Post-conditioning of macrophages with CDCs results in an alternatively
activated phenotype, which has been shown to improve prognosis following myocardial infarction.
Abbreviations: BMDM; bone marrow derived macrophages, DAMP; damage associated molecular
pattern, MMP; metallo-matrix proteinase; IL-10; interleukin-10, TGF-β; transforming growth factor-β,
CDC; cardiosphere-derived cells.
Int. J. Mol. Sci. 2019, 20, 2474 10 of 18
Funding: This research was funded by National Institutes of Health grants R01HL081863, by Innovative Research
Grant 16IRG27540027 and Grant-in-aid 16GRNT30810007 from the American Heart Association, and by the
Ingeborg v.F. McKee Fund of the Hawaii Community Foundation 17ADVC-86287 to WAB. JY was supported
by the National Institutes of Health grant F31HL139082. DJH was supported by the British Heart Foundation
(CS/14/3/31002), the National Institute for Health Research University College London Hospitals Biomedical
Research Centre, Duke-National University Singapore Medical School, Singapore Ministry of Health’s National
Medical Research Council under its Clinician Scientist-Senior Investigator scheme (NMRC/CSA-SI/0011/2017) and
Collaborative Centre Grant scheme (NMRC/CGAug16C006), and the Singapore Ministry of Education Academic
Research Fund Tier 2 (MOE2016-T2-2-021). HACF was supported by the SHF-Foundation (SHF/FG657P/2017)
and by the von Behring-Röntgen-Foundation (Marburg, Germany). Part of this work was performed within the
Russian Government Program of Competitive Growth of Kazan Federal University. This article is based upon
work from COST Action EU-CARDIOPROTECTION CA16225 supported by COST (European Cooperation in
Science and Technology).
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
CVD Cardiovascular diseases
DALYs Disability adjusted life-years
MI Myocardial infarction
PE Pulmonary embolism
LDL Low-density lipoprotein
ROS Reactive oxygen species
ER Endoplasmic reticulum
MMPs Matrix metalloproteinases
ECM Extracellular matrix
CXCLs Chemokine (C-X-C motif) ligands
CCLs Chemokine ligands
MIP Macrophage Inflammatory Proteins
RANTES Regulated on Activation, Normal T Cell Expressed and Secreted – CCL5
MCP Monocyte chemoattractant protein
PAMPs Pathogen-associated molecular patterns
DAMPs Damage-associated molecular patterns
PRRs Pattern recognition receptors
TLRs Toll-like receptors
MYD88 Myeloid differentiation primary response 88
IRAK-4 Interleukin-1 receptor-associated kinase 4
TRAF TNF receptor associated factor
IKKβ IκB kinase β
NF-κB Nuclear factor-kappa B
ILs Interleukins
IFN Interferon
NK Natural-killer cells
NO Nitric oxide
SR Scavenger receptors
MR Mannose receptors
TGF-β Transforming growth factor-β
MHC-II Major histocompatibility complex class II molecules
CCR Chemokine receptors
ARG 1 Arginase-1
GCR Glucocorticoid receptor
FN-1 Fibronectin-1
TRIB1 Tribbles homolog 1 is a protein kinase
VEGF Vascular endothelial growth factor
BMDM Bone marrow derived macrophages
CDC Cardiosphere-derived cells
GFP Green fluorescent protein
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